Lv1
30 积分 2023-01-06 加入
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis
3天前
已完结
Golidocitinib: First Approval
23天前
已完结
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase
1个月前
已完结
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase
1个月前
已关闭
Identification of novel inhibitors targeting KRAS-SOS1 interactions by structure-based drug design
1年前
已完结
Targeting RAS oncogenesis with SOS1 inhibitors
1年前
已完结
Abstract 1273: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, anin vivotool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction
1年前
已关闭
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
1年前
已完结
Targeting RAS oncogenesis with SOS1 inhibitors
1年前
已完结
Abstract 1273: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, anin vivotool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction
1年前
已关闭
皖公网安备34019202002308
